Skip to main content

Cartesian Therapeutics, Inc.

RNAC
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001453687

No open-market purchases or sales by Cartesian Therapeutics, Inc. insiders were filed in the last 90 days; 94 institutions reported holding it in 13F filings for Q2 2026, worth $90.4M in total; no superinvestor holds it.

Q3 2023 vs. Q2 2023

How the institutions holding Cartesian Therapeutics, Inc. changed between Q2 2023 and Q3 2023.

All holders in Q3 2023All holders in Q2 2023

13F holders of RNAC: Q2 2023 compared with Q3 2023
MeasureQ2 2023Q3 2023Change
Holders9287−5
Shares56.5M54.0M−2.51M (−4.4%)
Value$63.2M$57.2M−$6.04M (−9.6%)

New holders (8)

Institutions that held Cartesian Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.

Institutions new to RNAC in Q3 2023
InstitutionSharesValue% of portfolio
Madison Avenue Partners, LP4,008,019$4.25M0.60%
Gsa Capital Partners LLP290,258$308.0K0.03%
Deutsche Bank AG65,815$69.8K0.00%
Allspring Global Investments Holdings, LLC47,895$50.8K0.00%
SG Americas Securities, LLC41,938$44.0K0.00%
Belpointe Asset Management LLC26,400$28.0K0.00%
Manufacturers Life Insurance Company, The22,069$23.4K0.00%
Newbridge Financial Services Group, Inc.3,000$3.18K0.00%

Sold out (13)

Institutions that held Cartesian Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.